



Order ID 200432
 Provider Example Provider MD

Specimen
 Collected 05/30/2018
 Received 05/16/2018
Test Order
 Created 06/01/2018
 Reported 06/02/2018

Patient
Sample, Susan S
 Gender - DOB Female - 01/25/1974
 Identifier Received
 Exagen ID 300955

AVISE SLE Prognostic Test Report

Analyte	Value	Interpretation	Reference Range
+ Anti-C1q IgG	90 Units	POSITIVE	ELISA: <20 - Negative ≥20 - Positive
Anti-Ribosomal P IgG	8 Units	Negative	ELISA: <20 - Negative ≥20 - Positive
+ Anti-Phosphatidylserine/Prothrombin IgM	34 Units	POSITIVE	ELISA: <21 - Negative ≥21 - Positive
+ Anti-Phosphatidylserine/Prothrombin IgG	41 Units	POSITIVE	ELISA: <21 - Negative ≥21 - Positive
Anti-Cardiolipin IgM *	6 CU	Negative	ELISA: <20 - Negative ≥20 - Positive
Anti-Cardiolipin IgG *	7 CU	Negative	ELISA: <20 - Negative ≥20 - Positive
Anti-Cardiolipin IgA	3 CU	Negative	ELISA: <20 - Negative ≥20 - Positive
Anti-β2 Glycoprotein 1 IgM *	3 CU	Negative	ELISA: <21 - Negative ≥21 - Positive
Anti-β2 Glycoprotein 1 IgG *	5 CU	Negative	ELISA: <21 - Negative ≥21 - Positive
Anti-β2 Glycoprotein 1 IgA	6 CU	Negative	ELISA: <21 - Negative ≥21 - Positive

*Analyte was also reported on the AVISE Lupus/CTD Test Report of this Order

Test Method Description

Results were obtained by enzyme-linked immunosorbent (ELISA) for the quantitative determination of Anti-C1q IgG, Anti-Ribosomal P IgG and Anti-Phosphatidylserine/Prothrombin (PS/PT) antibodies (IgM and IgG). Antibodies against cardiolipin (IgM, IgG, IgA). β2-glycoprotein I (IgM, IgG, IgA) were determined using solid phase immunoassays with chemiluminescence detection.

References

1. INOVA Markers references and results (INOVA product inserts).
2. Yin et al. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. *Lupus*. 2012 Sep;21(10):1088-97.
3. Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. *Lupus*. 2011 Oct;20(12):1267-74. doi: 10.1177/0961203311411597. Epub 2011 Aug 3.
4. Hanly et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. *Ann Rheum Dis*. 2011 Oct;70(10):1726-32.
5. Akhter et al. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. *J Rheumatol*. 2013 Mar;40(3):282-6.



1261 Liberty Way, Vista CA
 CLIA# 05D1075048
 CAP# 7201051 | PFI# 8369

Laboratory Directors:
 Richard Safrin, MD
 Thierry Dervieux, PhD, DABCC

Provider Relations: 888.452.1522
 AVISE and the AVISE and Exagen logos are registered trademarks of Exagen, Inc. ©2019 All Rights Reserved

This test is used for clinical purposes, though results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research. It has not been cleared or approved by the FDA. Exagen is regulated under CLIA as qualified to perform high-complexity testing. SA1060(12/16)